CIK 0001649989
- Non-accelerated filer
- Smaller reporting company
Outlook Therapeutics, Inc.
Sign in to watch- Ticker
- OTLK
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Sep 30
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 383982704
- Phone
- +1 609-619-3990
- Business address
- 111 S. WOOD AVENUE, UNIT #100, ISELIN, NJ, 08830
- Former names
- Oncobiologics, Inc.
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market buy Director bought 27,708 shares at $1.69 ($46,827)
- 4 Open-market buy Director bought 47,160 shares at an average $1.48 ($69,694)
- 4 Open-market buy Director bought 175,132 shares at an average $1.47 ($256,970)
- 4 Other disposition Director disposed of 2,500,000 shares (other)
- 4 Other acquisition Director acquired 2,500,000 shares (other)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market buy CEO and President bought 25,000 shares at $1.39 ($34,750)
- 4 Open-market buy Chief Operating Officer bought 25,201 shares at $1.38 ($34,777)
- 4 Open-market buy Chief Commercial Officer bought 35,200 shares at $1.34 ($47,168)
- 4 Open-market buy Chief Operating Officer bought 10,000 shares at $1.42 ($14,200)
- 4 Open-market buy Director bought 10,000 shares at $1.39 ($13,900)
- 4 Open-market buy Director bought 18,000 shares at $1.40 ($25,200)
- 4 Open-market buy CEO and President bought 10,000 shares at $1.40 ($14,000)
- 4 Open-market buy Director bought 16,000,000 shares at $1.25 ($20,000,000)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
Page 6 of 16 · 305 filings